Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Grade 3 well-differentiated neuroendocrine tumour, drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
The Ki-67 boundary between grade 3 tumour and carcinoma is not sharp, and some cases can only be settled by molecular testing.
No trial has been run in grade 3 tumours alone; NETTER-2 and COMPOSE mix them with grade 2.
Whether platinum-etoposide, CAPTEM or radioligand therapy should come first in the fastest grade 3 tumours is unknown.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
PFS 23.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.